Share Price and Basic Stock Data
Last Updated: November 26, 2025, 7:17 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Decipher Labs Ltd operates in the pharmaceuticals sector, with its stock price currently standing at ₹10.3 and a market capitalization of ₹10.4 Cr. The company has experienced significant fluctuations in revenue, with sales recorded at ₹65.32 Cr for the fiscal year ending March 2022, but declining to ₹45.57 Cr in March 2023 and further to ₹35.88 Cr in March 2024. The trailing twelve months (TTM) sales were reported at ₹16.53 Cr, indicating a stark decrease in operational performance. Quarterly sales also reflect this downward trend, with the latest figures showing ₹7.49 Cr for September 2023, down from ₹12.12 Cr in September 2022. This declining trajectory raises concerns about the sustainability of its business model and market position, especially as it struggles to maintain consistent revenue against a backdrop of rising operational costs.
Profitability and Efficiency Metrics
The profitability of Decipher Labs has been under considerable pressure, as evidenced by its negative operating profit margin (OPM) of -113.70% reported for June 2025. The company’s operating profit over the recent fiscal years has seen a downward spiral, with an operating loss of ₹4.17 Cr in March 2023 and a further decline to -₹1.89 Cr in March 2025. The return on equity (ROE) stood at a mere 1.16%, while the return on capital employed (ROCE) was even lower at 4.67%, indicating ineffective utilization of capital. The cash conversion cycle was recorded at 68.12 days, which, while relatively manageable, suggests inefficiencies in managing receivables and inventory. The overall financial health is further indicated by the interest coverage ratio (ICR) of 0.00x, highlighting the inability to cover interest expenses, which poses a substantial risk to its financial stability.
Balance Sheet Strength and Financial Ratios
Decipher Labs’ balance sheet reveals significant weaknesses, particularly with regard to its liquidity and capital structure. The company reported no borrowings, which is a positive aspect; however, the absence of reserves raises questions about its financial cushion in times of distress. The price-to-book value (P/BV) ratio stands at 0.46x, suggesting that the stock is undervalued relative to its book value, but this also reflects investors’ skepticism about the company’s future profitability. The current ratio of 7.24x indicates strong short-term liquidity, but it may also suggest inefficiencies in asset utilization. The interest coverage ratio underscores a critical concern, as it stands at 0.00x, indicating that the company is not generating sufficient earnings to service its debt obligations, despite having no reported long-term debt.
Shareholding Pattern and Investor Confidence
The shareholding structure of Decipher Labs shows a significant public ownership of 83.57%, with promoters holding a stable 16.43% stake. This distribution indicates a lack of institutional investment, as foreign institutional investors (FIIs) and domestic institutional investors (DIIs) are not reported, which might reflect a lack of confidence in the company’s management or future prospects. The number of shareholders has gradually declined from 40,027 in December 2022 to 30,174 by June 2025, suggesting a potential exodus of retail investors amidst the company’s deteriorating performance. This trend could further erode market confidence and liquidity, making it difficult for the company to attract new investment and maintain a stable share price.
Outlook, Risks, and Final Insight
Looking ahead, Decipher Labs faces multiple risks that could hinder its recovery. The persistent decline in sales and profitability highlights operational challenges that need addressing for sustainable growth. Additionally, the company’s inability to generate positive cash flow raises concerns about its long-term viability. However, should Decipher Labs manage to reverse its revenue decline through strategic restructuring or new product introductions, it may regain investor confidence and improve its financial standing. Conversely, if operational inefficiencies continue unchecked, the risks of insolvency could increase. The company’s future hinges on its management’s ability to implement effective turnaround strategies while navigating the volatile pharmaceutical landscape, marked by intense competition and regulatory challenges.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Decipher Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.62 | 12.12 | 11.06 | 9.78 | 9.51 | 7.49 | 8.29 | 10.59 | 7.44 | 5.87 | 5.80 | 3.50 | 2.92 |
| Expenses | 13.36 | 12.98 | 14.02 | 13.63 | 9.65 | 9.66 | 8.16 | 9.38 | 6.13 | 7.20 | 6.43 | 10.08 | 6.24 |
| Operating Profit | -0.74 | -0.86 | -2.96 | -3.85 | -0.14 | -2.17 | 0.13 | 1.21 | 1.31 | -1.33 | -0.63 | -6.58 | -3.32 |
| OPM % | -5.86% | -7.10% | -26.76% | -39.37% | -1.47% | -28.97% | 1.57% | 11.43% | 17.61% | -22.66% | -10.86% | -188.00% | -113.70% |
| Other Income | 6.86 | 2.66 | -4.55 | 0.15 | 0.01 | 0.14 | 0.00 | 0.27 | 0.16 | 0.12 | 0.17 | 0.87 | 0.01 |
| Interest | 0.11 | 0.12 | 0.13 | 0.07 | 0.01 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.12 |
| Profit before tax | 5.91 | 1.58 | -7.75 | -3.89 | -0.25 | -2.14 | 0.01 | 1.16 | 1.36 | -1.33 | -0.58 | -5.84 | -3.43 |
| Tax % | 0.00% | 24.05% | 0.13% | 9.77% | 280.00% | -9.35% | 0.00% | -3.45% | 30.15% | 0.00% | 1.72% | -29.62% | 0.00% |
| Net Profit | 5.91 | 1.19 | -7.75 | -4.27 | -0.95 | -1.94 | 0.01 | 1.20 | 0.95 | -1.33 | -0.59 | -4.11 | -3.43 |
| EPS in Rs | 5.85 | 1.18 | -7.67 | -4.23 | -0.94 | -1.92 | 0.01 | 1.19 | 0.94 | -1.32 | -0.58 | -4.07 | -3.40 |
Last Updated: August 19, 2025, 8:20 pm
Below is a detailed analysis of the quarterly data for Decipher Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.92 Cr.. The value appears to be declining and may need further review. It has decreased from 3.50 Cr. (Mar 2025) to 2.92 Cr., marking a decrease of 0.58 Cr..
- For Expenses, as of Jun 2025, the value is 6.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.08 Cr. (Mar 2025) to 6.24 Cr., marking a decrease of 3.84 Cr..
- For Operating Profit, as of Jun 2025, the value is -3.32 Cr.. The value appears strong and on an upward trend. It has increased from -6.58 Cr. (Mar 2025) to -3.32 Cr., marking an increase of 3.26 Cr..
- For OPM %, as of Jun 2025, the value is -113.70%. The value appears strong and on an upward trend. It has increased from -188.00% (Mar 2025) to -113.70%, marking an increase of 74.30%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.87 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.86 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.13 Cr. (Mar 2025) to 0.12 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is -3.43 Cr.. The value appears strong and on an upward trend. It has increased from -5.84 Cr. (Mar 2025) to -3.43 Cr., marking an increase of 2.41 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -29.62% (Mar 2025) to 0.00%, marking an increase of 29.62%.
- For Net Profit, as of Jun 2025, the value is -3.43 Cr.. The value appears strong and on an upward trend. It has increased from -4.11 Cr. (Mar 2025) to -3.43 Cr., marking an increase of 0.68 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.40. The value appears strong and on an upward trend. It has increased from -4.07 (Mar 2025) to -3.40, marking an increase of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:32 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 16.53 |
| Expenses | 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 26.94 |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -10.41 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -62.98% |
| Other Income | 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 1.07 |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.50 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -9.84 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | |
| Net Profit | 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -8.11 |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -8.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 127.78% | 168.29% | 27.27% | 712.86% | -123.55% | 37.31% | -202.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | 40.51% | -141.02% | 685.58% | -836.41% | 160.86% | -239.69% |
Decipher Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -4400% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -15% |
| 3 Years: | -39% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -4% |
| Last Year: | -23% |
Last Updated: September 5, 2025, 3:11 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Diluted EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Cash EPS (Rs.) | -4.56 | -1.21 | -2.23 | 12.13 | 2.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Revenue From Operations / Share (Rs.) | 22.39 | 35.52 | 45.12 | 64.67 | 55.01 |
| PBDIT / Share (Rs.) | -5.85 | -0.53 | -1.05 | 13.56 | 4.05 |
| PBIT / Share (Rs.) | -6.32 | -0.98 | -1.48 | 12.71 | 3.24 |
| PBT / Share (Rs.) | -6.32 | -1.20 | -4.12 | 12.23 | 2.12 |
| Net Profit / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| NP After MI And SOA / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| PBDIT Margin (%) | -26.13 | -1.50 | -2.33 | 20.97 | 7.37 |
| PBIT Margin (%) | -28.24 | -2.76 | -3.27 | 19.64 | 5.89 |
| PBT Margin (%) | -28.24 | -3.37 | -9.12 | 18.91 | 3.85 |
| Net Profit Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| NP After MI And SOA Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| Return on Networth / Equity (%) | -22.22 | -7.66 | -11.55 | 47.10 | 10.24 |
| Return on Capital Employeed (%) | -27.94 | -4.54 | -6.17 | 41.60 | 15.30 |
| Return On Assets (%) | -19.71 | -4.98 | -9.52 | 27.13 | 3.62 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.04 | 0.27 | 0.49 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.04 | 0.42 | 0.63 |
| Asset Turnover Ratio (%) | 0.76 | 1.16 | 1.30 | 0.03 | 0.04 |
| Current Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Quick Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 |
| Interest Coverage Ratio (X) | 0.00 | -2.49 | -2.49 | 28.74 | 3.61 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | -6.70 | -0.03 | 24.89 | 2.24 |
| Enterprise Value (Cr.) | 8.05 | 5.60 | 7.86 | 48.39 | 35.56 |
| EV / Net Operating Revenue (X) | 0.35 | 0.15 | 0.17 | 0.74 | 0.64 |
| EV / EBITDA (X) | -1.36 | -10.36 | -7.39 | 3.53 | 8.68 |
| MarketCap / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| Price / BV (X) | 0.46 | 0.68 | 0.61 | 2.21 | 2.47 |
| Price / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| EarningsYield | -0.47 | -0.11 | -0.18 | 0.21 | 0.04 |
After reviewing the key financial ratios for Decipher Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.56. This value is below the healthy minimum of 3. It has decreased from -1.21 (Mar 24) to -4.56, marking a decrease of 3.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 22.39. It has decreased from 35.52 (Mar 24) to 22.39, marking a decrease of 13.13.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -5.85. This value is below the healthy minimum of 2. It has decreased from -0.53 (Mar 24) to -5.85, marking a decrease of 5.32.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -0.98 (Mar 24) to -6.32, marking a decrease of 5.34.
- For PBT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -1.20 (Mar 24) to -6.32, marking a decrease of 5.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For PBDIT Margin (%), as of Mar 25, the value is -26.13. This value is below the healthy minimum of 10. It has decreased from -1.50 (Mar 24) to -26.13, marking a decrease of 24.63.
- For PBIT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -2.76 (Mar 24) to -28.24, marking a decrease of 25.48.
- For PBT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -3.37 (Mar 24) to -28.24, marking a decrease of 24.87.
- For Net Profit Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 5. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 8. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For Return on Networth / Equity (%), as of Mar 25, the value is -22.22. This value is below the healthy minimum of 15. It has decreased from -7.66 (Mar 24) to -22.22, marking a decrease of 14.56.
- For Return on Capital Employeed (%), as of Mar 25, the value is -27.94. This value is below the healthy minimum of 10. It has decreased from -4.54 (Mar 24) to -27.94, marking a decrease of 23.40.
- For Return On Assets (%), as of Mar 25, the value is -19.71. This value is below the healthy minimum of 5. It has decreased from -4.98 (Mar 24) to -19.71, marking a decrease of 14.73.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 1.16 (Mar 24) to 0.76, marking a decrease of 0.40.
- For Current Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Quick Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 2. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -2.49 (Mar 24) to 0.00, marking an increase of 2.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -6.70 (Mar 24) to 0.00, marking an increase of 6.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.05. It has increased from 5.60 (Mar 24) to 8.05, marking an increase of 2.45.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.35, marking an increase of 0.20.
- For EV / EBITDA (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 5. It has increased from -10.36 (Mar 24) to -1.36, marking an increase of 9.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.46, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.11 (Mar 24) to -0.47, marking a decrease of 0.36.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Decipher Labs Ltd:
- Net Profit Margin: -22.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -27.94% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -22.22% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -22.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Hyderabad Telangana 500081 | cs@decipherlabs.in www.decipherlabs.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sushant Mohan Lal | Executive Director |
| Mr. Janaki Ram Ajjarapu | Non Executive Director |
| Mr. G Venkateswara Rao | Independent Director |
| Mrs. Lakshmi Vijaya Nimmala | Independent Director |
| Mrs. Gayathri Raghuram | Independent Director |